Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

Table 4 Direct health care annual costs (2015 USD)

	Average annual costs	References
Health care costs (per episode/year)
Myocardial infarction	$18627	Bergenheim et al., 2012 [12]
Heart failure	$14118	Bergenheim et al., 2012 [12]
Stroke	$7939	Bergenheim et al., 2012 [12]
Hypoglycemia events requiring medical assistance	$199	Bergenheim et al., 2012 [12]
Severe hypoglycemia event	$146	Bergenheim et al., 2012 [12]
Weight gain	$289	Bergenheim et al., 2012 [12]
Drug cost (per patient/year)
Metformin, generic drug	$24	NADAC (January 2015) [22]
Dipeptidyl peptidase-4 inhibitor, brand	$3500 ($3401; $3599)	NADAC (January 2015) [22]
Sulfonylurea (glipizide), generic	$16	NADAC (January 2015) [22]
Insulin glargine, brand	$3646	NADAC (January 2015) [22]

All drug costs and direct health-state costs were expressed in 2015 US dollars ($) per patient/year

ISSN: 1472-6963